Shots:

• The 48wk. P-II trial and 12wk. P-Ib trial evaluates pemvidutide vs PBO in a ratio (1:1:1:1) in 320 & 54 patients. In the (MOMENTUM) trial, pemvidutide (1.2/1.8/2.4mg) showed mean weight losses of 7.3%/9.4%/10.7% vs 1.0%; 8.2%/10.6%/11.9% vs 0.8% with baseline body weight ≤115kg
• ~50% achieved ≥10% weight loss, ~20% achieved ≥15% weight loss @24wks., robust reductions in waist circumference, serum lipids & BP without increases in heart rate, treatment discontinuation rates (24.0% vs 28.2%). The trial is expected to be completed in Q4’23 & will initiate a P-II biopsy NASH trial in mid-2023
• In the P-Ib trial, mean weight losses of 4.4%/6.1%/7.7% at 12wks. over mean weight gain of 0.8% in the PBO group with no hyperglycemic AEs & SAEs, no AEs leads to study discontinuation, glucose homeostasis was maintained with no changes in fasting glucose or HbA1c in both trials

Ref: Altimmune | Image: Altimmune

Related News:- Altimmune Reports 24-Week (12-Week Extension) Trial Results of Pemvidutide for the Treatment of Non-Alcoholic Fatty Liver Disease